Natural Alternatives reports USD 142.52 million sales for Natural Alternatives International stock

Published on 10/20/2026 at 21:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fiscal 2026 sales rose 10.00 percent to USD 142.52 million. Natural Alternatives International stock costs EUR 1.04 on October 20, 2026.

Fiscal sales and market figures

Natural Alternatives reported fiscal 2026 sales of USD 142.52 million on September 28, 2026.
The fiscal 2026 net loss reached USD 20.70 million after a USD 10.40 million impairment charge.
Natural Alternatives International stock cost EUR 1.04 at Lang & Schwarz on October 20, 2026 at 9:16 p.m. CEST.

NAII, US6388423021, Illustration mit AI erstellt.

Natural Alternatives International (ISIN US6388423021) reported fiscal 2026 sales of USD 142.52 million, up 10.00 percent from USD 129.86 million a year earlier, in results released on September 28, 2026. The company also reported a wider loss, keeping profitability as the central issue for Natural Alternatives International stock.

At Lang & Schwarz, the stock was trading at EUR 1.04 on October 20, 2026 at 9:16 p.m. CEST.

Sales grew while losses widened

According to Markets Insider, fourth-quarter fiscal 2026 net sales rose 1.90 percent to USD 34.51 million from USD 33.87 million. The quarterly net loss widened to USD 13.54 million from USD 7.22 million, or USD 2.23 per diluted share from USD 1.20.

The result included a non-recurring, non-cash impairment charge of USD 10.41 million tied to the underutilized Carlsbad manufacturing facility. Excluding that charge, the quarterly net loss would have been USD 3.10 million, or USD 0.52 per diluted share.

Manufacturing drives the revenue mix

Private-label contract manufacturing sales increased 11.00 percent to USD 134.60 million in fiscal 2026, while CarnoSyn royalty, licensing and raw material sales declined 2.00 percent to USD 7.90 million. The manufacturing division therefore accounted for 94.50 percent of annual sales, according to Yahoo Finance.

Cash and cash equivalents fell to USD 7.40 million as of June 30, 2026, from USD 12.30 million a year earlier. The company also reported USD 7.70 million of outstanding credit-facility borrowings and USD 17.70 million of remaining borrowing capacity.

Losses remain the valuation risk

Natural Alternatives had total assets of USD 126.45 million on June 30, 2026, compared with USD 151.94 million one year earlier. Its fiscal 2026 net loss was USD 20.70 million, versus USD 13.58 million in fiscal 2025, while diluted loss per share widened to USD 3.43 from USD 2.28.

The company is consolidating United States manufacturing operations into its Vista facility and reviewing strategic alternatives, including possible mergers, acquisitions, joint ventures or a sale. These plans were included in the September 28, 2026 results release and add an operational response to the capacity-utilization problem.

Stock price and trading context

On the Nasdaq, Natural Alternatives International stock was trading at USD 1.16 on October 20, 2026 at 3:20 p.m. ET. The same quote showed a market capitalization of USD 7.3 million, a 52-week range of USD 1.08 to USD 4.96 and volume of 44,608 shares.

The company develops and manufactures nutritional supplements for private-label customers and also licenses its CarnoSyn beta-alanine ingredient. Its fiscal 2026 figures show higher sales, but the USD 20.70 million annual loss and lower cash balance leave execution and capacity utilization as the key financial questions.